Chronic overload of SEPT4, a parkin substrate that aggregates in Parkinson's disease, causes behavioral alterations but not neurodegeneration in mice

Molecular Brain

Volumn 6, Issue 1, 2013, Pages

  Ageta Ishihara, Natsumi ^a   Yamakado, Hodaka ^b   Morita, Takao ^a   Hattori, Satoko ^c,d,e   Takao, Keizo ^c,d,e   Miyakawa, Tsuyoshi ^c,d,e   Takahashi, Ryosuke ^b,e   Kinoshita, Makoto ^a,e  

^a NAGOYA UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE FOR PHYSIOLOGICAL SCIENCES   (Japan)

^d FUJITA HEALTH UNIVERSITY   (Japan)

^e JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Parkin; Septin; Systematic behavioral screening; Transgenic mouse

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE TRANSPORTER; PARKIN; PRION PROTEIN; SEPT4 PROTEIN; SEPTIN; SEPTIN5 PROTEIN; TYROSINE 3 MONOOXYGENASE; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; VIRUS VECTOR; DOPAMINE; METHAMPHETAMINE; PEPTIDE; SEPT4 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMISTRY; BIPOLAR DISORDER; BRAIN; CONTROLLED STUDY; CORPUS STRIATUM; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; GENE OVEREXPRESSION; HISTOCHEMISTRY; LEWY BODY; MALE; MOTOR COORDINATION; MOUSE; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOGENICITY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN AGGREGATION; PROTEIN LOAD; PROTEIN MODIFICATION; SCHIZOPHRENIA; SOCIAL BEHAVIOR; TRANSGENIC MOUSE; VIRUS ATTENUATION; WILD TYPE; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; CHEMISTRY; CIRCADIAN RHYTHM; COMPLICATION; DRUG EFFECTS; ENZYME SPECIFICITY; ENZYMOLOGY; EXPLORATORY BEHAVIOR; HUMAN; METABOLISM; NEOSTRIATUM; PATHOLOGY; PROTEIN QUATERNARY STRUCTURE; RAT; SOLUBILITY;

MAMMALIA; MUS; MUS MUSCULUS; RATTUS;

ALPHA-SYNUCLEIN; ANIMALS; BEHAVIOR, ANIMAL; CIRCADIAN RHYTHM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; EXPLORATORY BEHAVIOR; HUMANS; METHAMPHETAMINE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOSTRIATUM; NERVE DEGENERATION; PARKINSON DISEASE; PEPTIDES; PROTEIN STRUCTURE, QUATERNARY; RATS; SEPTINS; SOLUBILITY; SUBSTRATE SPECIFICITY; TYROSINE 3-MONOOXYGENASE; UBIQUITIN-PROTEIN LIGASES;

EID: 84881167474     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/1756-6606-6-35     Document Type: Article

References (40)

1. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Pennington K, Beasley CL, Dicker P, Fagan A, English J, Pariante CM, Wait R, Dunn MJ, Cotter DR, Mol psychiatry 2008 13 1102 1117 10.1038/sj.mp.4002098 17938637
2. Common proteomic changes in the hippocampus in schizophrenia and bipolar disorder and particular evidence for involvement of cornu ammonis regions 2 and 3. Focking M, Dicker P, English JA, Schubert KO, Dunn MJ, Cotter DR, Arch gen psychiatry 2011 68 477 488 10.1001/archgenpsychiatry.2011.43 21536977
3. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM, Proc Natl Acad Sci USA 2000 97 13354 13359 10.1073/pnas.240347797 11078524
4. SEPT5-v2 is a parkin-binding protein. Choi P, Snyder H, Petrucelli L, Theisler C, Chong M, Zhang Y, Lim K, Chung KK, Kehoe K, D'Adamio L, et al. Brain res 2003 117 179 189 10.1016/S0169-328X(03)00318-8
5. Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function. Periquet M, Corti O, Jacquier S, Brice A, J neurochem 2005 95 1259 1276 10.1111/j.1471-4159.2005. 03442.x 16150055
6. Neurotoxicity and behavioral deficits associated with Septin 5 accumulation in dopaminergic neurons. Son JH, Kawamata H, Yoo MS, Kim DJ, Lee YK, Kim S, Dawson TM, Zhang H, Sulzer D, Yang L, et al. J neurochem 2005 94 1040 1053 10.1111/j.1471-4159.2005.03257.x 16092945
7. Expression of Lewy body protein septin 4 in postmortem brain of Parkinson's disease and control subjects. Shehadeh L, Mitsi G, Adi N, Bishopric N, Papapetropoulos S, Mov Disord 2009 24 204 210 10.1002/mds.22306 18951507
8. The septin CDCrel-1 binds syntaxin and inhibits exocytosis. Beites CL, Xie H, Bowser R, Trimble WS, Nat neurosci 1999 2 434 439 10.1038/8100 10321247
9. Dopamine-dependent neurodegeneration in rats induced by viral vector-mediated overexpression of the parkin target protein, CDCrel-1. Dong Z, Ferger B, Paterna JC, Vogel D, Furler S, Osinde M, Feldon J, Bueler H, Proc Natl Acad Sci USA 2003 100 12438 12443 10.1073/pnas.2132992100 14530399
10. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, Meloni EG, Wu N, Ackerson LC, Klapstein GJ, et al. J biol chem 2003 278 43628 43635 10.1074/jbc.M308947200 12930822
11. Alterations of social interaction through genetic and environmental manipulation of the 22q11.2 gene Sept5 in the mouse brain. Harper KM, Hiramoto T, Tanigaki K, Kang G, Suzuki G, Trimble W, Hiroi N, Human mol gen 2012 21 3489 3499 10.1093/hmg/dds180
12. Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of -synuclein neurotoxicity. Ihara M, Yamasaki N, Hagiwara A, Tanigaki A, Kitano A, Hikawa R, Tomimoto H, Noda M, Takanashi M, Mori H, et al. Neuron 2007 53 519 533 10.1016/j.neuron.2007.01.019 17296554
13. Conformation-specific binding of -synuclein to novel protein partners detected by phage display and NMR spectroscopy. Woods WS, Boettcher JM, Zhou DH, Kloepper KD, Hartman KL, Ladror DT, Qi Z, Rienstra CM, George JM, J biol chem 2007 282 34555 34567 10.1074/jbc.M705283200 17893145
14. Association of the cytoskeletal GTP-binding protein Sept4/H5 with cytoplasmic inclusions found in Parkinson's disease and other synucleinopathies. Ihara M, Tomimoto H, Kitayama H, Morioka Y, Akiguchi I, Shibasaki H, Noda M, Kinoshita M, J biol chem 2003 278 24095 24102 10.1074/jbc.M301352200 12695511
15. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Borchelt DR, Davis J, Fischer M, Lee MK, Slunt HH, Ratovitsky T, Regard J, Copeland NG, Jenkins NA, Sisodia SS, et al. Genet Anal 1996 13 159 163 10.1016/S1050-3862(96)00167-2 9117892
16. Synuclein is phosphorylated in synucleinopathy lesions. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Watsubo T, Nat cell biol 2002 4 160 164 11813001
17. Designing mouse behavioral tasks relevant to autistic-like behaviors. Crawley JN, Mental retard dev disabil res rev 2004 10 248 258 10.1002/mrdd.20039
18. Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice. Moy SS, Nadler JJ, Perez A, Barbaro RP, Johns JM, Magnuson TR, Piven J, Crawley JN, Genes brain behav 2004 3 287 302 10.1111/j.1601-1848.2004.00076.x 15344922
19. The detection and measurement of locomotor deficits in a transgenic mouse model of Huntington's disease are task- and protocol-dependent: influence of non-motor factors on locomotor function. Pallier PN, Drew CJ, Morton AJ, Brain res bull 2009 78 347 355 10.1016/j.brainresbull.2008.10.007 19010400
20. The biochemistry of Parkinson's disease. Cookson MR, Annu rev biochem 2005 74 29 52 10.1146/annurev.biochem.74.082803.133400 15952880
21. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. Ko HS, von Coelln R, Sriram SR, Kim SW, Chung KK, Pletnikova O, Troncoso J, Johnson B, Saffary R, Goh EL, et al. J Neurosci 2005 25 7968 7978 10.1523/JNEUROSCI.2172-05.2005 16135753
22. Pael-R transgenic mice crossed with parkin deficient mice displayed progressive and selective catecholaminergic neuronal loss. Wang HQ, Imai Y, Inoue H, Kataoka A, Iita S, Nukina N, Takahashi R, J neurochem 2008 107 171 185 10.1111/j.1471-4159.2008.05607.x 18691389
23. Aggregate formation and toxicity by wild-type and R621C synphilin-1 in the nigrostriatal system of mice using adenoviral vectors. Krenz A, Falkenburger BH, Gerhardt E, Drinkut A, Schulz JB, J neurochem 2009 108 139 146 10.1111/j.1471-4159.2008.05755.x 19094062
24. Use of viral vectors to create animal models for Parkinson's disease. Low K, Aebischer P, Neurobiol dis 2012 48 189 201 10.1016/j.nbd.2011.12.038 22227451
25. Genome-wide scan of reading ability in affected sibling pairs with attention-deficit/hyperactivity disorder: unique and shared genetic effects. Loo SK, Fisher SE, Francks C, Ogdie MN, MacPhie IL, Yang M, McCracken JT, McGough JJ, Nelson SF, Monaco AP, et al. Mol psychiatry 2004 9 485 493 10.1038/sj.mp.4001450 14625563
26. Craniofacial dysmorphism and developmental disorders among children with chromosomal microdeletions and duplications of unknown significance. Gannon WT, Martinez JE, Anderson SJ, Swingle HM, J Dev Behav Pediatr 2011 32 600 604 10.1097/DBP.0b013e31823299d6 21918468
27. Molecular mechanisms and diagnosis of chromosome 22q11.2 rearrangements. Emanuel BS, Dev disabil res rev 2008 14 11 18 10.1002/ddrr.3 18636632
28. The 22q11.2 microdeletion: fifteen years of insights into the genetic and neural complexity of psychiatric disorders. Drew LJ, Crabtree GW, Markx S, Stark KL, Chaverneff F, Xu B, Mukai J, Fenelon K, Hsu PK, Gogos JA, et al. Int J Dev Neurosci 2011 29 259 281 10.1016/j.ijdevneu.2010.09.007 20920576
29. Mice overexpressing genes from the 22q11 region deleted in velo-cardio-facial syndrome/DiGeorge syndrome have middle and inner ear defects. Funke B, Epstein JA, Kochilas LK, Lu MM, Pandita RK, Liao J, Bauerndistel R, Schuler T, Schorle H, Brown MC, et al. Human mol gen 2001 10 2549 2556 10.1093/hmg/10.22.2549
30. A 200-kb region of human chromosome 22q11.2 confers antipsychotic- responsive behavioral abnormalities in mice. Hiroi N, Zhu H, Lee M, Funke B, Arai M, Itokawa M, Kucherlapati R, Morrow B, Sawamura T, Agatsuma S, Proc Natl Acad Sci USA 2005 102 19132 19137 10.1073/pnas.0509635102 16365290
31. Expression and analysis of properties of septin CDCrel-1 in exocytosis. Beites CL, Peng XR, Trimble WS, Meth enzymol 2001 329 499 510 11210570
32. The septin CDCrel-1 is dispensable for normal development and neurotransmitter release. Peng XR, Jia Z, Zhang Y, Ware J, Trimble WS, Mol cellular biol 2002 22 378 387 10.1128/MCB.22.1.378-387.2002
33. Superfluous role of mammalian septins 3 and 5 in neuronal development and synaptic transmission. Tsang CW, Fedchyshyn M, Harrison J, Xie H, Xue J, Robinson PJ, Wang LY, Trimble WS, Mol cell biol 2008 28 7012 7029 10.1128/MCB.00035-08 18809578
34. Abnormalities of presynaptic protein CDCrel-1 in striatum of rats reared in social isolation: relevance to neural connectivity in schizophrenia. Barr AM, Young CE, Sawada K, Trimble WS, Phillips AG, Honer WG, Eur J Neurosci 2004 20 303 307 10.1111/j.0953-816X.2004.03457.x 15245502
35. Sept5 deficiency exerts pleiotropic influence on affective behaviors and cognitive functions in mice. Suzuki G, Harper KM, Hiramoto T, Sawamura T, Lee M, Kang G, Tanigaki K, Buell M, Geyer MA, Trimble WS, et al. Human mol gen 2009 18 1652 1660 10.1093/hmg/ddp086
36. Light/dark transition test for mice. Takao K, Miyakawa T, J Vis Exp 2006 104 10.3791/104
37. Impact of brain-behavior phenotypying of genetically-engineered mice on research of neuropsychiatric disorders. Takao K, Yamasaki N, Miyakawa T, Neurosci res 2007 58 124 132 10.1016/j.neures.2007.02.009 17524507
38. Elevated plus maze for mice. Komada M, Takao K, Miyakawa T, J Vis Exp 2008 1088 10.3791/1088
39. Local knockdown of genes in the brain using small interfering RNA: a phenotypic comparison with knockout animals. Salahpour A, Medvedev IO, Beaulieu JM, Gainetdinov RR, Caron MG, Biol psychiatry 2007 61 65 69 10.1016/j.biopsych. 2006.03.020 16712807
40. Differential localization of septins in the mouse brain. Kinoshita A, Noda M, Kinoshita M, J comp neurol 2000 428 223 239 10.1002/1096-9861(20001211) 428:2<223::AID-CNE3>3.0.CO;2-M 11064363